EFFICACY OF OFLOXACIN IN EXPERIMENTAL STAPHYLOCOCCUS-AUREUS ENDOCARDITIS

被引:26
作者
KAATZ, GW
SEO, SM
BARRIERE, SL
ALBRECHT, LM
RYBAK, MJ
机构
[1] WAYNE STATE UNIV,COLL PHARM & ALLIED HLTH PROFESS,DETROIT,MI 48201
[2] UNIV DETROIT,DETROIT RECEIVING HOSP,CTR HLTH,DEPT PHARM SERV,DETROIT,MI 48201
[3] UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT PHARMACEUT SERV,DIV INFECT DIS,LOS ANGELES,CA 90024
[4] UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT PHARMACOL,LOS ANGELES,CA 90024
[5] UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,LOS ANGELES,CA 90024
关键词
D O I
10.1128/AAC.34.2.257
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The efficacy of ofloxacin was compared with that of vancomycin in the therapy of experimental Staphylococcus aureus endocarditis. Rabbits infected with either a methicillin-susceptible (MSSA-1199) or a methicillin-resistant (MRSA-494) test strain were treated with ofloxacin (20 mg/kg of body weight every 8 h) or vancomycin (17.5 mg/kg of body weight every 6 h) for 4 days. The antimicrobial agents were found to be equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and in renal and splenic tissue of animals infected with either test strain. The drugs were of equal efficacy in curing MRSA-494 endocarditis. No resistance to ofloxacin emerged in either test strain during therapy. We conclude that in this model ofloxacin is as efficacious as vancomycin and that, unlike for other fluoroquinolones we have evaluated, resistance to the drug does not develop during therapy of this serious S. aureus infection.
引用
收藏
页码:257 / 260
页数:4
相关论文
共 14 条
[1]   COMPARATIVE-EVALUATION OF RECENTLY DEVELOPED QUINOLONE COMPOUNDS - WITH A NOTE ON THE FREQUENCY OF RESISTANT MUTANTS [J].
CULLMANN, W ;
STIEGLITZ, M ;
BAARS, B ;
OPFERKUCH, W .
CHEMOTHERAPY, 1985, 31 (01) :19-28
[2]   RESISTANCE STUDIES WITH OFLOXACIN [J].
FELMINGHAM, D ;
FOXALL, P ;
OHARE, MD ;
WEBB, G ;
GHOSH, G ;
GRUNEBERG, RN .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 :27-34
[3]   ENOXACIN COMPARED WITH VANCOMYCIN FOR THE TREATMENT OF EXPERIMENTAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS [J].
GILBERT, M ;
BOSCIA, JA ;
KOBASA, WD ;
KAYE, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (03) :461-463
[4]  
Jones R., 1985, MANUAL CLIN MICROBIO, P972
[5]   EFFICACY OF FLEROXACIN IN EXPERIMENTAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS [J].
KAATZ, GW ;
SEO, SM ;
BARRIERE, SL ;
ALBRECHT, LM ;
RYBAK, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :519-521
[6]   CIPROFLOXACIN AND RIFAMPIN, ALONE AND IN COMBINATION, FOR THERAPY OF EXPERIMENTAL STAPHYLOCOCCUS-AUREUS ENDOCARDITIS [J].
KAATZ, GW ;
SEO, SM ;
BARRIERE, SL ;
ALBRECHT, LM ;
RYBAK, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1184-1187
[7]   CIPROFLOXACIN VERSUS VANCOMYCIN IN THE THERAPY OF EXPERIMENTAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS [J].
KAATZ, GW ;
BARRIERE, SL ;
SCHABERG, DR ;
FEKETY, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (04) :527-530
[8]   THE EMERGENCE OF RESISTANCE TO CIPROFLOXACIN DURING TREATMENT OF EXPERIMENTAL STAPHYLOCOCCUS-AUREUS ENDOCARDITIS [J].
KAATZ, GW ;
BARRIERE, SL ;
SCHABERG, DR ;
FEKETY, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 20 (05) :753-758
[9]   PHARMACOKINETICS OF OFLOXACIN AFTER PARENTERAL AND ORAL-ADMINISTRATION [J].
LODE, H ;
HOFFKEN, G ;
OLSCHEWSKI, P ;
SIEVERS, B ;
KIRCH, A ;
BORNER, K ;
KOEPPE, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (09) :1338-1342
[10]  
Mitsuhashi S, 1988, Rev Infect Dis, V10 Suppl 1, pS27